An Introduction to Dermatology
Autoimmunity and deregulation of the immune system contribute to many skin diseases including systemic sclerosis, dermatomyositis, psoriasis, vitiligo, alopecia areata and lichen sclerosus; as well as inflammatory diseases such as hidradenitis suppurativa, allergic contact dermatitis and atopic eczema; and also autoimmune blistering diseases, including pemphigus vulgaris, bullous pemphigoid, epidermolysis bullosa acquisita and dermatitis herpetiformis. Established treatments include systemic corticosteroids and immunosuppressive therapies, while new therapies in development include biologic therapies targeting cytokines such as tumour necrosis factor alpha (TNF-alpha) and interleukins IL-23 and IL-17; enzymes such as Janus kinase-1 (JAK-1); and the regulatory proteinretinoic acid receptor-related-orphan-receptor-gamma t (RORγt).
Browse video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and peer-reviewed articles from the journal portfolio. This is complemented by a range of educational activities from our expert faculty, with patient outcomes at the forefront.
Diamant Thaçi, EADV 2020 – Long-term Efficacy of Tildrakizumab in Psoriasis
It was an honour to talk with Diamant Thaçi (University of Lübeck, Lübeck, Germany) about the reSURFACE clinical studies and in particular, long-term data from reSURFACE 2 (NCT01729754). Results from the study, which investigated the anti-IL-23p19 monoclonal antibody, tildrakizumab in the treatment of patients with moderate-to-severe plaque psoriasis, were presented in the abstract entitled ‘Long-term […]
Lluís Puig, EADV 2020 – New Therapeutic Targets in Psoriasis
We were delighted to be able to speak with Lluís Puig (Universitat Autònoma de Barcelona School of Medicine, Barcelona, Spain) about novel pathophysiology-based therapeutic agents in the treatment of psoriasis. His full presentation entitled ‘New therapeutic targets based on pathophysiology’ was presented at the EADV Virtual Congress 2020. Questions Could you give us a brief […]
Mehdi Rashighi, EADV 2020 – JAK inhibitors in Vitiligo
We were delighted to catch up with Mehdi Rashighi (University of Massachusetts Medical School, Boston, MA, USA) to discuss the use of JAK inhibitors in the treatment of vitiligo. Questions What are the limitations of current therapeutic approaches for vitiligo? (0:26) What is the role of the JAK pathway in the pathogenesis of vitiligo? (0:56) […]
Giovanni Damiani, EADV 2020 – Highlights from the meeting
Dr Giovanni Damiani (University of Milan; Clinical Dermatology, IRCCS Instituto Ortopedico Galeazzi) gave us some of his key highlights from EADV 2020. Disclosures: Dr Giovanni Damiani has no disclosures to report. Support: Interview and filming supported by Touch Medical Media. Filmed as highlights of the 29th EADV Virtual Congress 2020.
Linda Gold Stein, EADV 2020 – Roflumilast Cream in Chronic Plaque Psoriasis
We caught up with Linda Gold Stein (Henry Ford Health System, Detroit, MI, USA) to discuss the results of the phase 2B study of roflumilast cream in adults with chronic plaque psoriasis (ClinicalTrials.gov identifier: NCT03638258). Questions 1. What are the limitations of current topical therapies for chronic plaque psoriasis? (0:06) 2. What is the mechanism […]
Kim Papp, EADV 2020 – Sonelokinab for Chronic Plaque Psoriasis
We were delighted to discuss with Kim Papp (Probity Medical Research, Waterloo, ON, Canada) the results of the phase IIb study assessing the efficacy, safety and tolerability of sonelokinab (M1095), and IL-17 A/F nanobody, in patients with moderate-to-severe chronic plaques psoriasis (Clinical Trial Identifier: NCT03384745) Questions What are the major unmet needs in the treatment […]
Tiago Torres, EADV 2020 – The IL-23 Pathway in Psoriasis
We were delighted to have the opportunity to speak with Expert Faculty member Tiago Torres (Centro Hospitalar Universitário do Porto, Portugal) about the biology of the IL-23 pathway in psoriasis and the therapeutic use of IL-23 inhibitors. Questions Could you give us a brief overview of the role of the IL-23 in the pathogenesis of psoriasis? […]
Journal articles and more to your inbox
Get the latest clinical insights from touchIMMUNOLOGYSign me up!